Hepatitis C is an infectious disease caused by the hepatitis C virus, which infiltrates the liver and other organs. It causes inflammation and damage to DNA regulatory genes.
According to a 2007 report, hepatitis C (HCV) causes more deaths each year in the U.S. than human immunodeficiency virus (HIV). HCV is a primary reason why people need liver transplants. More than 4 million Americans are infected with HCV (NIH 2009; Rosen 2011; Holmberg 2011; Rubin 2011).
Approximately 75%-85% of people infected with HCV develop a chronic infection and face the risk of advanced liver fibrosis, cirrhosis, cancer, and other complications (Chen 2006).
Many people have the disease for decades before it is diagnosed. This is because HCV infection usually causes only minor symptoms until liver damage is advanced (Mayo Clinic 2011).
In some cases, liver abnormalities detected during routine blood work can suggest to a physician that a patient might have an HCV infection. This may allow treatment to begin before the disease reaches a critical stage. Therefore, proactive blood testing could be helpful in discovering an undetected HCV infection (McDonald 2010).
Though current standard of care has met with somewhat limited success and is burdened by considerable side effects, exciting findings reveal potential for underutilized drug strategies, such as metformin and thymosin alpha-1, to complement conventional treatment and improve outcomes in hepatitis C (Poo 2008; Baek 2007; Ciancio 2010; Yu 2012; Romero-Gómez 2009; Nkontchou 2011).
In this protocol, you will learn about how the hepatitis C virus is transmitted and the consequences of an infection. You will also discover that many people may not realize they are infected, and early detection can save lives. Lastly, you will find out about breakthroughs on the horizon that promise to vastly improve medical treatment outcomes as well as several natural compounds that target multiple aspects of hepatitis C.